California Public Employees Retirement System held its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. California Public Employees Retirement System owned 0.07% of Corbus Pharmaceuticals Holdings worth $289,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CRBP. Raymond James Financial Services Advisors Inc. raised its position in shares of Corbus Pharmaceuticals Holdings by 5.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 403,886 shares of the biopharmaceutical company’s stock worth $3,332,000 after buying an additional 21,125 shares during the period. Bank of New York Mellon Corp raised its position in shares of Corbus Pharmaceuticals Holdings by 7.7% in the first quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 1,511 shares during the period. SG Americas Securities LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter worth approximately $148,000. Quantbot Technologies LP acquired a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter worth approximately $114,000. Finally, IPG Investment Advisors LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter worth approximately $109,000. Hedge funds and other institutional investors own 31.78% of the company’s stock.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) traded up 1.46% on Tuesday, hitting $6.95. The stock had a trading volume of 141,961 shares. The company’s market cap is $349.03 million. The stock’s 50-day moving average price is $6.24 and its 200 day moving average price is $7.04. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $3.73 and a 52 week high of $10.78.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.50 million. On average, analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post ($0.66) EPS for the current year.

TRADEMARK VIOLATION WARNING: “California Public Employees Retirement System Holds Position in Corbus Pharmaceuticals Holdings, Inc. (CRBP)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/29/california-public-employees-retirement-system-holds-position-in-corbus-pharmaceuticals-holdings-inc-crbp.html.

A number of research analysts have recently commented on the company. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a report on Tuesday, June 13th. BidaskClub lowered Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Finally, Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Sunday, May 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $20.50.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.